首页> 外文期刊>European review for medical and pharmacological sciences. >A novel homozygous TPM1 mutation in familial pediatric hypertrophic cardiomyopathy and in silico screening of potential targeting drugs
【24h】

A novel homozygous TPM1 mutation in familial pediatric hypertrophic cardiomyopathy and in silico screening of potential targeting drugs

机译:家族儿科肥厚性心肌病和潜在靶向药物硅筛选的一种新型纯合TPM1突变

获取原文
获取外文期刊封面目录资料

摘要

OBJECTIVE: Familial hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease. While sarcomeric gene mutations explain many HCM cases, the genetic basis of about half of HCM cases remains elusive. Here we aimed to identify the gene causing HCM in a non-consanguineous Saudi Arabian family with affected family members and a history of sudden death. The impact of the identified mutation on protein structure and potential drug targets were evaluated in silico. MATERIALS AND METHODS: Triplets (two HCM subjects and one patent ductus arteriosus (PDA) case) and unaffected parents were screened by targeted next-generation sequencing (NGS) for 181 candidate cardiomyopathy genes. In silico structural and functional analyses, including protein modeling, structure prediction, drug screening, drug binding, and dynamic simulations were performed to explore the potential pathogenicity of the variant and to identify candidate drugs. RESULTS: A homozygous missense mutation in exon 1 of TMP1 (assembly GRCh37-chr15: 63340781; GA) was identified in the triplets [two HCM and one patent ductus arteriosus (PDA)] that substituted glycine for arginine at codon 3 (p.Gly3Arg). The parents were heterozygous for the variant. The mutation was predicted to cause a significant and deleterious change in the TPM1 protein structure that slightly affected drug binding, stability, and conformation. In addition, we identified several putative TPM1-targeting drugs through structure-based in silico screening. CONCLUSIONS: TPM1 mutations are a common cause of HCM and other congenital heart defects. To date, TPM1 has not been associated with isolated PDA; to our knowledge, this is the first report of the homozygous missense variation p.Gly3Arg in TPM1 associated with familial autosomal recessive pediatric HCM and PDA. The identified candidate TPM1 inhibitors warrant further prospective investigation.
机译:目的:家族肥厚性心肌病(HCM)是最常见的遗传心脏病。虽然Sarcomeric基因突变解释了许多HCM病例,但大约一半的HCM病例的遗传基础仍然难以捉摸。在这里,我们旨在识别导致HCM在非近亲沙特阿拉伯家族中的基因,受影响的家庭成员和猝死的历史。在硅中评价了鉴定突变对蛋白质结构和潜在药物靶标的影响。材料和方法:通过针对181名候选心肌病基因的靶向下一代测序(NGS)筛选三胞胎(两个HCM受试者和一粒术术术(PDA)案例)和未受影响的父母。在硅结构和功能分析中,进行包括蛋白质建模,结构预测,药物筛选,药物结合和动态模拟,以探讨变体的潜在致病性和鉴定候选药物。结果:TMP1的外显子1(组件GRCH37-CH1115:63340781; G> A)中纯合的致命突变在三胞胎[两个HCM和一项专利导管(PDA)]中鉴定在密码子3的精氨酸中取代甘氨酸(P. .gly3arg)。父母对变体杂合。预测突变导致TPM1蛋白质结构中的显着和有害的变化,其略微影响药物结合,稳定性和构象。此外,我们通过基于Silico筛选的结构鉴定了几种推定的TPM1靶向药物。结论:TPM1突变是HCM和其他先天性心脏缺陷的常见原因。迄今为止,TPM1尚未与孤立的PDA相关联;据我们所知,这是与家族性常染色体隐性小儿HCM和PDA相关的TPM1中纯合物畸变变异P.Gly3arg的第一份报告。确定的候选TPM1抑制剂需要进一步的预期调查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号